Cargando…

Human iPSC-derived hepatocyte system models cholestasis with tight junction protein 2 deficiency

BACKGROUND & AIMS: The truncating mutations in tight junction protein 2 (TJP2) cause progressive cholestasis, liver failure, and hepatocyte carcinogenesis. Due to the lack of effective model systems, there are no targeted medications for the liver pathology with TJP2 deficiency. We leveraged the...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Chao Zheng, Ogawa, Hiromi, Ng, Soon Seng, Chen, Xindi, Kishimoto, Eriko, Sakabe, Kokoro, Fukami, Aiko, Hu, Yueh-Chiang, Mayhew, Christopher N., Hellmann, Jennifer, Miethke, Alexander, Tasnova, Nahrin L., Blackford, Samuel J.I., Tang, Zu Ming, Syanda, Adam M., Ma, Liang, Xiao, Fang, Sambrotta, Melissa, Tavabie, Oliver, Soares, Filipa, Baker, Oliver, Danovi, Davide, Hayashi, Hisamitsu, Thompson, Richard J., Rashid, S. Tamir, Asai, Akihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8904612/
https://www.ncbi.nlm.nih.gov/pubmed/35284810
http://dx.doi.org/10.1016/j.jhepr.2022.100446
_version_ 1784664993255391232
author Li, Chao Zheng
Ogawa, Hiromi
Ng, Soon Seng
Chen, Xindi
Kishimoto, Eriko
Sakabe, Kokoro
Fukami, Aiko
Hu, Yueh-Chiang
Mayhew, Christopher N.
Hellmann, Jennifer
Miethke, Alexander
Tasnova, Nahrin L.
Blackford, Samuel J.I.
Tang, Zu Ming
Syanda, Adam M.
Ma, Liang
Xiao, Fang
Sambrotta, Melissa
Tavabie, Oliver
Soares, Filipa
Baker, Oliver
Danovi, Davide
Hayashi, Hisamitsu
Thompson, Richard J.
Rashid, S. Tamir
Asai, Akihiro
author_facet Li, Chao Zheng
Ogawa, Hiromi
Ng, Soon Seng
Chen, Xindi
Kishimoto, Eriko
Sakabe, Kokoro
Fukami, Aiko
Hu, Yueh-Chiang
Mayhew, Christopher N.
Hellmann, Jennifer
Miethke, Alexander
Tasnova, Nahrin L.
Blackford, Samuel J.I.
Tang, Zu Ming
Syanda, Adam M.
Ma, Liang
Xiao, Fang
Sambrotta, Melissa
Tavabie, Oliver
Soares, Filipa
Baker, Oliver
Danovi, Davide
Hayashi, Hisamitsu
Thompson, Richard J.
Rashid, S. Tamir
Asai, Akihiro
author_sort Li, Chao Zheng
collection PubMed
description BACKGROUND & AIMS: The truncating mutations in tight junction protein 2 (TJP2) cause progressive cholestasis, liver failure, and hepatocyte carcinogenesis. Due to the lack of effective model systems, there are no targeted medications for the liver pathology with TJP2 deficiency. We leveraged the technologies of patient-specific induced pluripotent stem cells (iPSC) and CRISPR genome-editing, and we aim to establish a disease model which recapitulates phenotypes of patients with TJP2 deficiency. METHODS: We differentiated iPSC to hepatocyte-like cells (iHep) on the Transwell membrane in a polarized monolayer. Immunofluorescent staining of polarity markers was detected by a confocal microscope. The epithelial barrier function and bile acid transport of bile canaliculi were quantified between the two chambers of Transwell. The morphology of bile canaliculi was measured in iHep cultured in the Matrigel sandwich system using a fluorescent probe and live-confocal imaging. RESULTS: The iHep differentiated from iPSC with TJP2 mutations exhibited intracellular inclusions of disrupted apical membrane structures, distorted canalicular networks, altered distribution of apical and basolateral markers/transporters. The directional bile acid transport of bile canaliculi was compromised in the mutant hepatocytes, resembling the disease phenotypes observed in the liver of patients. CONCLUSIONS: Our iPSC-derived in vitro hepatocyte system revealed canalicular membrane disruption in TJP2 deficient hepatocytes and demonstrated the ability to model cholestatic disease with TJP2 deficiency to serve as a platform for further pathophysiologic study and drug discovery. LAY SUMMARY: We investigated a genetic liver disease, progressive familial intrahepatic cholestasis (PFIC), which causes severe liver disease in newborns and infants due to a lack of gene called TJP2. By using cutting-edge stem cell technology and genome editing methods, we established a novel disease modeling system in cell culture experiments. Our experiments demonstrated that the lack of TJP2 induced abnormal cell polarity and disrupted bile acid transport. These findings will lead to the subsequent investigation to further understand disease mechanisms and develop an effective treatment.
format Online
Article
Text
id pubmed-8904612
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-89046122022-03-10 Human iPSC-derived hepatocyte system models cholestasis with tight junction protein 2 deficiency Li, Chao Zheng Ogawa, Hiromi Ng, Soon Seng Chen, Xindi Kishimoto, Eriko Sakabe, Kokoro Fukami, Aiko Hu, Yueh-Chiang Mayhew, Christopher N. Hellmann, Jennifer Miethke, Alexander Tasnova, Nahrin L. Blackford, Samuel J.I. Tang, Zu Ming Syanda, Adam M. Ma, Liang Xiao, Fang Sambrotta, Melissa Tavabie, Oliver Soares, Filipa Baker, Oliver Danovi, Davide Hayashi, Hisamitsu Thompson, Richard J. Rashid, S. Tamir Asai, Akihiro JHEP Rep Research Article BACKGROUND & AIMS: The truncating mutations in tight junction protein 2 (TJP2) cause progressive cholestasis, liver failure, and hepatocyte carcinogenesis. Due to the lack of effective model systems, there are no targeted medications for the liver pathology with TJP2 deficiency. We leveraged the technologies of patient-specific induced pluripotent stem cells (iPSC) and CRISPR genome-editing, and we aim to establish a disease model which recapitulates phenotypes of patients with TJP2 deficiency. METHODS: We differentiated iPSC to hepatocyte-like cells (iHep) on the Transwell membrane in a polarized monolayer. Immunofluorescent staining of polarity markers was detected by a confocal microscope. The epithelial barrier function and bile acid transport of bile canaliculi were quantified between the two chambers of Transwell. The morphology of bile canaliculi was measured in iHep cultured in the Matrigel sandwich system using a fluorescent probe and live-confocal imaging. RESULTS: The iHep differentiated from iPSC with TJP2 mutations exhibited intracellular inclusions of disrupted apical membrane structures, distorted canalicular networks, altered distribution of apical and basolateral markers/transporters. The directional bile acid transport of bile canaliculi was compromised in the mutant hepatocytes, resembling the disease phenotypes observed in the liver of patients. CONCLUSIONS: Our iPSC-derived in vitro hepatocyte system revealed canalicular membrane disruption in TJP2 deficient hepatocytes and demonstrated the ability to model cholestatic disease with TJP2 deficiency to serve as a platform for further pathophysiologic study and drug discovery. LAY SUMMARY: We investigated a genetic liver disease, progressive familial intrahepatic cholestasis (PFIC), which causes severe liver disease in newborns and infants due to a lack of gene called TJP2. By using cutting-edge stem cell technology and genome editing methods, we established a novel disease modeling system in cell culture experiments. Our experiments demonstrated that the lack of TJP2 induced abnormal cell polarity and disrupted bile acid transport. These findings will lead to the subsequent investigation to further understand disease mechanisms and develop an effective treatment. Elsevier 2022-02-01 /pmc/articles/PMC8904612/ /pubmed/35284810 http://dx.doi.org/10.1016/j.jhepr.2022.100446 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Research Article
Li, Chao Zheng
Ogawa, Hiromi
Ng, Soon Seng
Chen, Xindi
Kishimoto, Eriko
Sakabe, Kokoro
Fukami, Aiko
Hu, Yueh-Chiang
Mayhew, Christopher N.
Hellmann, Jennifer
Miethke, Alexander
Tasnova, Nahrin L.
Blackford, Samuel J.I.
Tang, Zu Ming
Syanda, Adam M.
Ma, Liang
Xiao, Fang
Sambrotta, Melissa
Tavabie, Oliver
Soares, Filipa
Baker, Oliver
Danovi, Davide
Hayashi, Hisamitsu
Thompson, Richard J.
Rashid, S. Tamir
Asai, Akihiro
Human iPSC-derived hepatocyte system models cholestasis with tight junction protein 2 deficiency
title Human iPSC-derived hepatocyte system models cholestasis with tight junction protein 2 deficiency
title_full Human iPSC-derived hepatocyte system models cholestasis with tight junction protein 2 deficiency
title_fullStr Human iPSC-derived hepatocyte system models cholestasis with tight junction protein 2 deficiency
title_full_unstemmed Human iPSC-derived hepatocyte system models cholestasis with tight junction protein 2 deficiency
title_short Human iPSC-derived hepatocyte system models cholestasis with tight junction protein 2 deficiency
title_sort human ipsc-derived hepatocyte system models cholestasis with tight junction protein 2 deficiency
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8904612/
https://www.ncbi.nlm.nih.gov/pubmed/35284810
http://dx.doi.org/10.1016/j.jhepr.2022.100446
work_keys_str_mv AT lichaozheng humanipscderivedhepatocytesystemmodelscholestasiswithtightjunctionprotein2deficiency
AT ogawahiromi humanipscderivedhepatocytesystemmodelscholestasiswithtightjunctionprotein2deficiency
AT ngsoonseng humanipscderivedhepatocytesystemmodelscholestasiswithtightjunctionprotein2deficiency
AT chenxindi humanipscderivedhepatocytesystemmodelscholestasiswithtightjunctionprotein2deficiency
AT kishimotoeriko humanipscderivedhepatocytesystemmodelscholestasiswithtightjunctionprotein2deficiency
AT sakabekokoro humanipscderivedhepatocytesystemmodelscholestasiswithtightjunctionprotein2deficiency
AT fukamiaiko humanipscderivedhepatocytesystemmodelscholestasiswithtightjunctionprotein2deficiency
AT huyuehchiang humanipscderivedhepatocytesystemmodelscholestasiswithtightjunctionprotein2deficiency
AT mayhewchristophern humanipscderivedhepatocytesystemmodelscholestasiswithtightjunctionprotein2deficiency
AT hellmannjennifer humanipscderivedhepatocytesystemmodelscholestasiswithtightjunctionprotein2deficiency
AT miethkealexander humanipscderivedhepatocytesystemmodelscholestasiswithtightjunctionprotein2deficiency
AT tasnovanahrinl humanipscderivedhepatocytesystemmodelscholestasiswithtightjunctionprotein2deficiency
AT blackfordsamuelji humanipscderivedhepatocytesystemmodelscholestasiswithtightjunctionprotein2deficiency
AT tangzuming humanipscderivedhepatocytesystemmodelscholestasiswithtightjunctionprotein2deficiency
AT syandaadamm humanipscderivedhepatocytesystemmodelscholestasiswithtightjunctionprotein2deficiency
AT maliang humanipscderivedhepatocytesystemmodelscholestasiswithtightjunctionprotein2deficiency
AT xiaofang humanipscderivedhepatocytesystemmodelscholestasiswithtightjunctionprotein2deficiency
AT sambrottamelissa humanipscderivedhepatocytesystemmodelscholestasiswithtightjunctionprotein2deficiency
AT tavabieoliver humanipscderivedhepatocytesystemmodelscholestasiswithtightjunctionprotein2deficiency
AT soaresfilipa humanipscderivedhepatocytesystemmodelscholestasiswithtightjunctionprotein2deficiency
AT bakeroliver humanipscderivedhepatocytesystemmodelscholestasiswithtightjunctionprotein2deficiency
AT danovidavide humanipscderivedhepatocytesystemmodelscholestasiswithtightjunctionprotein2deficiency
AT hayashihisamitsu humanipscderivedhepatocytesystemmodelscholestasiswithtightjunctionprotein2deficiency
AT thompsonrichardj humanipscderivedhepatocytesystemmodelscholestasiswithtightjunctionprotein2deficiency
AT rashidstamir humanipscderivedhepatocytesystemmodelscholestasiswithtightjunctionprotein2deficiency
AT asaiakihiro humanipscderivedhepatocytesystemmodelscholestasiswithtightjunctionprotein2deficiency